Medullary thyroid carcinoma (MTC) · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-MEN2-CARRIER-SURVEILLANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-MTC |
| Sources | SRC-ATA-THYROID-2015 SRC-NCCN-BCELL-2025 SRC-NCCN-THYROID-2025 |
Notes
STUB — v0.2-B confirmed-carrier surveillance pathway (MEN2). Sibling — IND-MEN2-CARRIER-INTENSIFIED (aggressive plan_track).
Used By
Actionability
BMA-CALCITONIN-MTC-MEN2-SURVEILLANCE- Serum calcitonin is a highly specific biomarker for medullary thyroid carcinoma (MTC) — p...BMA-METANEPHRINES-PHEO-VHL-MEN2-SURVEILLANCE- Plasma free metanephrines are the gold-standard biochemical test for pheochromocytoma and...
Algorithms
ALGO-MEN2-CARRIER-PROPHYLACTIC-THYROIDECTOMY-TIMING- ALGO-MEN2-CARRIER-PROPHYLACTIC-THYROIDECTOMY-TIMING
Indication
IND-MEN2-CARRIER-INTENSIFIED- IND-MEN2-CARRIER-INTENSIFIED
Red flag
RF-MEN2-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the RET proto-oncogene — MEN...RF-MEN2-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Multiple Endocrine Neoplasia type 2 (MEN2A or MEN2B, RET-dr...